Article

Power and sample size.

Department of Biostatistical Sciences, Wake Forest University Health Sciences, Winston-Salem, NC, USA.
Methods in molecular biology (Clifton, N.J.) (Impact Factor: 1.29). 02/2007; 404:377-408. DOI: 10.1007/978-1-59745-530-5_19
Source: PubMed

ABSTRACT In this chapter, we discuss the concept of statistical power and show how the sample size can be chosen to ensure a desired power. Power is the probability of rejecting the null hypothesis when the null hypothesis is false, that is the probability of saying there is a difference when a difference actually exists. An underpowered study does not have a sufficiently large sample size to answer the research question of interest. An overpowered study has too large a sample size and wastes resources. We will show how the power and required sample size can be calculated for several common types of studies, mention software that can be used for the necessary calculations, and discuss additional considerations.

0 Bookmarks
 · 
128 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To re-analyse bicycle overtaking data collected by Walker (2007) with a view to assess factors associated with close passing (<1 m), to adjust for other observed factors in a multivariable analysis, and to assess the extent to which the sample size in the original analysis may have contributed to spurious results. A re-analysis of 2,355 motor vehicle passing events recorded by Walker that includes information on cyclist's distance to the kerb, vehicle size and colour, city of observation, time of day, whether the event occurred while in a bikelane and helmet wearing. Each variable was considered for a final, multivariable model using purposeful selection of variables. The analysis was repeated using multiple logistic regression with passing distance dichotomised by the one metre rule. Bootstrap p-values were computed using sample sizes computed from conventional values of power and effect size. The previously observed significant association between passing distance and helmet wearing was not found when dichotomised by the one metre rule. Other factors were found to be significantly associated with close passing including cyclists' distance to the kerb, vehicle size and city of observation (Salisbury or Bristol, UK). P-values from bootstrap samples indicate the significance of helmet wearing resulted from an overly large sample size. After re-analysis of Walker's data, helmet wearing is not associated with close motor vehicle passing. The results, however, highlight other more important factors that may inform effective bicycle safety strategies.
    PLoS ONE 01/2013; 8(9):e75424. · 3.73 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In light of the growing epidemics of nonalcoholic fatty liver disease (NAFLD), identification and validation of the novel biochemical surrogate markers for nonalcoholic steatohepatitis (NASH) are paramount to reduce the necessity for liver biopsy. The availability of such markers has tremendous potential to radically alter the management strategies of NAFLD patients and to monitor the disease activity. Although current biomarkers do not entirely fulfill the many requirements for the identification of patients with NASH, they should not discourage our quest, but remind us that we need to cognize the challenges ahead.
    World Journal of Gastroenterology 09/2009; 15(34):4346-7. · 2.55 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background:There is no disease activity index (DAI) currently available that can objectively assess the disease status of intestinal Behçet's disease (BD). The aim of this study was to develop a novel specific DAI for intestinal BD through a prospective study.Methods:Items included in the index were produced and graded by experts in intestinal BD. Two separate cohorts of patients (weighting and validation cohorts) with intestinal BD were prospectively enrolled, and their clinical and laboratory data were collected. Through weighting items by multiple regression modeling, the DAI for intestinal BD (DAIBD) was derived using the weighting cohort and validated using the validation cohort. The index's responsiveness was evaluated using a longitudinal cohort derived from the weighting cohort at a follow-up visit 2–3 months later.Results:A total of 110 patients with intestinal BD were enrolled in the weighting cohort. Eight of the 17 items selected by the experts accounted for 86.8% of the physician's global assessment (PGA) variance. The DAIBD calculated with gradations of weighted items correlated more strongly with PGA (r = 0.850) than did the Crohn's disease activity index (CDAI) (r = 0.649) in 50 patients of the validation cohort. Furthermore, quiescent, mild, moderate, and severe could be discriminated using the best cutoff scores. The DAIBD showed much higher responsiveness than did the CDAI (r = 0.812 vs. 0.645, respectively) in 109 patients in the longitudinal cohort.Conclusions:This novel DAIBD is an easy, valid, and responsive index to assess disease activity and can be useful to physicians who treat intestinal BD. Inflamm Bowel Dis 2011
    Inflammatory Bowel Diseases 04/2010; 17(2):605 - 613. · 5.12 Impact Factor

Full-text (2 Sources)

View
6 Downloads
Available from
Jun 16, 2014